Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Taysha Gene Therapies Inc
(NQ:
TSHA
)
2.110
+0.040 (+1.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Taysha Gene Therapies Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Recap: Taysha Gene Therapies Q4 Earnings
March 31, 2022
Taysha Gene Therapies (NASDAQ:TSHA) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Taysha Gene Therapies's Earnings Outlook
March 30, 2022
Taysha Gene Therapies (NASDAQ:TSHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial
January 31, 2022
Taysha Gene Therapies Inc (NASDAQ: TSHA) has
Via
Benzinga
Taysha Gene Plans Protocol Amendment After Patient Death In Gene Therapy Trial
January 27, 2022
Taysha Gene Therapies Inc (NASDAQ: TSHA) reported
Via
Benzinga
Earnings Scheduled For March 31, 2022
March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Via
Benzinga
Taysha Gene Therapies Earnings Conference Call Is Coming Up, Here's What You Need To Know
March 25, 2022
Taysha Gene Therapies (NASDAQ:TSHA) will host a conference call at 08:00 AM ET on March 31, 2022, to discuss Q4 2021 earnings results. How to Attend Taysha Gene Therapies (TSHA)...
Via
Benzinga
Analyst Ratings For Taysha Gene Therapies
August 18, 2021
Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst rat...
Via
Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2022
March 09, 2022
Upgrades Roth Capital upgraded the previous rating for Hudson Technologies Inc (NASDAQ:HDSN) from Neutral to Buy. For the fourth quarter, Hudson Technologies had an EPS of $0.13,...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 14, 2022
On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 08, 2022
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
March 01, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...
Via
Benzinga
Two Insider Moonshots Rising on Sudden Buying
February 10, 2022
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
February 22, 2022
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to...
Via
Benzinga
Executives Buy Around $62M Of 3 Stocks
February 07, 2022
The Nasdaq index jumped more than 200 points on Friday after Amazon.com, Inc. (NASDAQ: AMZN) reported better-than-expected earnings for its fourth quarter.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 20, 2022
Gainers TCR2 Therapeutics (NASDAQ:TCRR) s...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 06, 2022
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
January 19, 2022
During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...
Via
Benzinga
Stocks Hitting New 52-Week Lows Today
January 03, 2022
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...
Via
Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...
Via
Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
December 26, 2021
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
December 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...
Via
Benzinga
Taysha Gene's Epilepsy Candidate Shows Encouraging Action In Preclinical Studies
December 07, 2021
Taysha Gene Therapies Inc (NASDAQ: TSHA) announced a late-breaking abstract and poster presentation on preclinical data for TSHA-105 for SLC13A5-related epilepsy....
Via
Benzinga
Taysha Gene Therapies, Inc. (TSHA) Q3 2021 Earnings Call Transcript
November 11, 2021
TSHA earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Taysha's Rare Epilepsy Gene Therapy Receives European Orphan Drug Tag
August 25, 2021
The European Commission has granted Orphan Drug designation to Taysha Gene Therapies Inc's (NASDAQ: TSHA) TSHA-105, AAV9-based gene therapy for SLC13A5-...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.